Mosaic Therapeutics Appoints Dr. Barry Davies as CSO

Mosaic Therapeutics Appoints Dr. Barry Davies as CSO

Mosaic Therapeutics, Ltd. ("Mosaic" or "The Company"), a targeted oncology therapeutics company dedicated to solving the complexities of cancer to power new combination therapies for patients, today announced the appointment of Dr. Barry Davies to CSO, where he will lead the management of the company's Scientific Strategy and Research and Development teams.

Barry joins Mosaic with over 25 years of experience in drug discovery, including 19 years at AstraZeneca, where he most recently held the position of Senior Director Global Project Leader. During his time with AstraZeneca, he led multiple projects across phases from lead optimization to proof-of-concept clinical trials for the recently approved Capivasertib/Truqap. Previously, Barry held other leadership roles within AstraZeneca, including Senior Director, Clinical and Translational Scientific Alliances, where he was responsible for partnerships and collaborations in Europe and the Asia Pacific region.

Barry holds a BSC (Hons) Class I in Biochemistry and a PhD in Mechanisms of Breast Cancer Metastasis from the University of Liverpool. After postdoctoral work in Professor Bruce Ponder's laboratory in Cambridge, he founded his own research group at the Northern Institute for Cancer Research, University of Newcastle, where he was group leader, senior lecturer and Cancer Research UK grant holder.

"Barry's extensive experience and expertise in early oncology drug discovery and development will be a significant asset to Mosaic. We are pleased to welcome him to lead the research and development team."said Magda Jonikas, CEO of Mosaic Therapeutics.“Barry’s deep understanding of cancer biology and early drug development will be invaluable to the company as we advance our pipeline of targeted drug combinations in novel biomarker-defined settings, enabling us to deliver precision medicines to patients who currently have few therapeutic options.”

Barry Davies, CSO, Mosaic Therapeutics, commented:"Mosaic's pedigree is impressive, and the potential of its data science platform coupled with deeply characterized preclinical models to identify new combination therapies within oncology is very exciting. I am very excited to join the company at this pivotal stage and look forward to working with the leadership and scientific teams to advance the programs."

Learn more about Mosaic's molecular-guided approach to oncology medicine:

Sources: